Equity Story Group is pleased to present the Investor Verse workshop event with Australia's leading biotech experts.
Hear from the CEOs of three ASX-listed biotechs, medically qualified founders, and investment advisors with deep knowledge of the biotech sector.
Our panel - flying in from Melbourne, Adelaide and Perth - will be in Terrigal for this one-time event.
If you've always wanted to understand how to break into the lucrative and exciting biotech sector - previously the domain of expert investors - this event can't be missed.
Dr Michael Baker is the CEO & Managing Director of Arovella Therapeutics (ASX: ALA), a pre-clinical stage company developing personalised therapies for oncology, including cell therapies. He has a deep background in scientific research, drug development and venture investing in the life sciences sector.
At Arovella, Michael manages teams in Australia, America and research collaborations in the UK. Michael has led the strategy development at Arovella, including licensing technologies from world-class universities and research institutes, initiating and managing pre-clinical studies, capital raising and business development.
Dr Duthy is an Executive Director of Neurotech International.
With over 20 years of direct financial market and executive level/Board experience with ASX listed companies, Dr Duffy is a Director and Founder of Nemean Group, which provides corporate advisory and investor relations (IR) services in the Life Sciences and Technology sectors. This included an IR/Corporate Development consultancy role with Nova Eye Medical (ASX:EYE), during which time a $100 million all-cash sale of their Lasers & Ultrasound business to Lumibird Group was completed (2020). He has also provided IR advisory services to Limeade (ASX:LME), which announced a $112 million all cash takeover by WebMD Health Services in June 2023, representing a 325% premium to the prevailing market price.
Prior to establishing Nemean Group in October 2018, Dr Duthy was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX), which was sold to CDH Investments in September 2018 for A$1.9 billion and remains the largest medical device transaction in Australian corporate history. Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies having raised in excess of $300 million. He is a Member of the Australian Institute of Company Directors (MAICD).
In addition, Tom is a Director of Invex Therapeutics and Non-Executive Chairman of Arovella Therapeutics Limited.
Dr Leearne Hinch is a seasoned biotechnology CEO and entrepreneur with a proven track record in corporate strategy, business management, capital raising, investor relations, M&A, business development and partnering.
She is CEO of Melbourne-based biotech INOVIQ Ltd (ASX:IIQ) that is pioneering next-generation diagnostics and therapeutics to enhance patient outcomes in cancer and neurodegenerative diseases. Leearne has successfully led INOVIQ’s transformation from a single-asset diagnostics company to a diversified biotech, through M&A, developing a robust cancer diagnostics and therapeutics pipeline, securing a global commercial partner for its proprietary exosome capture tools and building a strong team of 20 personnel.
INOVIQ’s product portfolio includes 2 products in-market, 2 clinical-stage cancer diagnostics and an early-stage exosome therapeutic for solid tumours. The company is well-funded and positioned to capitalise on its existing product portfolio while exploring strategic M&A opportunities for growth.
David Tildesley stablished Equity Story - delivering fantastic stock picking results with a trending twist.
A unique and incredibly successive trading method for all traders, David will demonstrate The Cincinnati Trading Method.
Reece holds a Bachelor of Business and Finance from Murdoch University, an MBA from the University of Canberra, and a Graduate Diploma in Financial Planning with Kaplan.
Reece worked as a Trader in the City of London and as a Stockbroker in Perth prior to joining Merchant. During his financial career he has managed and traded his way through economic and market cycles. His long-term investment approach and care for his client’s needs and objectives is critically important to him.
Through Merchant Group he offers a specialised investment management service to a select group of high-net-worth and retail clients.
Shane White lives in Terrigal with his family, and is a long term share investor and trader who splits his time among managing his family office investment portfolio and heading up the Wealth and Capital Markets divisions for Equity Story Securities (a division of EQS).
Shane is a big believer in identifying excellent (often undervalued) assets and companies with great management teams. He believes in having "skin in the game" (Shane owns shares in all of the companies being highlighted at the event).
Shane also owns and manages corporate integrity consultancy Pinnacle Integrity, while in his spare time he surfs and plays golf (both poorly).
Connect with Shane on LinkedIn.
Any information provided prior to or during the event is general advice only and not personal financial or investment advice. Whilst these shares can be purchased openly on the public market by anyone, investors are encouraged to do their own research and seek their own personal advice.
Skillion Spaces are venue managers for this event and are not presenting advice or information. Interest and enquiries for the content of this event should be forwarded to event hosts: Shane White, Equity Story Group, and Merchant Biotech Fund.
